You just read:

Regeneron and Sanofi Announce Positive Dupilumab Topline Results from Two Phase 3 Trials in Inadequately Controlled Moderate-to-Severe Atopic Dermatitis Patients

News provided by

Regeneron Pharmaceuticals, Inc.

Apr 01, 2016, 01:00 ET